Checkmate Pharmaceuticals, Inc.
DelistedCIK 1651431fmd_0PM3NGDBFW7YRJ96VG1HSKER9DManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Jan 01, 2019 to Mar 31, 2022, 12 periods
Checkmate Pharmaceuticals, Inc. financials: quick answers
Annual figures as filed with the SEC. Each number links to the filing it came from and to its proof.
| Metric | FY2021 | FY2020 | Change | Source |
|---|---|---|---|---|
| Operating income | -$61.5 million | -$36.9 million | 10-K 2022-03-30 · proof | |
| Net income | -$61.4 million | -$36.9 million | 10-K 2022-03-30 · proof | |
| Cash from operating activities | -$53.7 million | -$38.1 million | 10-K 2022-03-30 · proof | |
| Free cash flow | -$54.6 million | 10-K 2022-03-30 · proof | ||
| Total assets | $78.8 million | $133.1 million | -40.8% | 10-K 2022-03-30 · proof |
| Total liabilities | $9.4 million | $7.9 million | +19.1% | 10-K 2022-03-30 · proof |
| Cash and cash equivalents | $50.7 million | $43.1 million | +17.7% | 10-K 2022-03-30 · proof |
- What was Checkmate Pharmaceuticals, Inc.'s operating income in fiscal 2021?
- Checkmate Pharmaceuticals, Inc. reported operating income of -$61.5 million for fiscal 2021 (the year ended Dec 31, 2021), against -$36.9 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2022. SEC
- What was Checkmate Pharmaceuticals, Inc.'s net income in fiscal 2021?
- Checkmate Pharmaceuticals, Inc. reported net income of -$61.4 million for fiscal 2021 (the year ended Dec 31, 2021), against -$36.9 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2022. SEC
- What was Checkmate Pharmaceuticals, Inc.'s cash from operating activities in fiscal 2021?
- Checkmate Pharmaceuticals, Inc. reported cash from operating activities of -$53.7 million for fiscal 2021 (the year ended Dec 31, 2021), against -$38.1 million the year before. Source: the 10-K filed with the SEC on Mar 30, 2022. SEC
- What was Checkmate Pharmaceuticals, Inc.'s free cash flow in fiscal 2021?
- Checkmate Pharmaceuticals, Inc. reported free cash flow of -$54.6 million for fiscal 2021 (the year ended Dec 31, 2021). Source: the 10-K filed with the SEC on Mar 30, 2022. SEC
- What are Checkmate Pharmaceuticals, Inc.'s total assets?
- As of Dec 31, 2021, Checkmate Pharmaceuticals, Inc. reported total assets of $78.8 million, against $133.1 million a year earlier (-40.8%). Source: the 10-K filed with the SEC on Mar 30, 2022. SEC
- What are Checkmate Pharmaceuticals, Inc.'s total liabilities?
- As of Dec 31, 2021, Checkmate Pharmaceuticals, Inc. reported total liabilities of $9.4 million, against $7.9 million a year earlier (+19.1%). Source: the 10-K filed with the SEC on Mar 30, 2022. SEC
- What are Checkmate Pharmaceuticals, Inc.'s cash and cash equivalents?
- As of Dec 31, 2021, Checkmate Pharmaceuticals, Inc. reported cash and cash equivalents of $50.7 million, against $43.1 million a year earlier (+17.7%). Source: the 10-K filed with the SEC on Mar 30, 2022. SEC
Read from the FinancialMD API on Nov 13, 2026. Values change only when a new filing is made; see the Financials tab for every period and as-of replay.
The same numbers for an agent, with proof on every value:
curl "https://api.financial.md/v1/company/financials/income_statement/standardized?company=cik:1651431&period_type=annual&limit=5"Information only, not investment advice.